FindTrial
Sign In

OXALIPLATINE KABI 5 mg/ml

DRUG3 trials

Sponsors

Institut Gustave Roussy, Hospices Civils De Lyon, Fondation Franc.Cancerologie Digestive

Conditions

Adult patients with intermediate low or mid rectal adenocarcinoma to be treated with total neoadjuvant therapy (TNT) potentially eligible for rectal preservation.Resectable borderline pancreatic adenocarcinomaThe patients enrolled in IMMUNORARE will be adult patients with 5 rare cancers: -Cohort 1: Peritoneal mesotheliomas (PM) -Cohort 2: Gestational trophoblastic tumors (GTT) -Cohort 3: B3 thymomas and thymic carcinomas (TET) -Cohort 4: Anaplastic thyroid carcinomas (ATC) -Cohort 5: GEP-NET & carcinoid tumors (GEP-NET/TCT/UP-NET) Patients will have advanced/metastatic cancers found to be progressive/resistant after at least one previous line of standard systemic treatment.

Phase 2

IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficacy of the IMMUNOtherapy with Domvanalimab + Zimberelimab combination in patients with advanced RARE cancers
SuspendedCTIS2024-517254-99-00
Hospices Civils De LyonThe patients enrolled in IMMUNORARE will be adult patients with 5 rare cancers: -Cohort 1: Peritoneal mesotheliomas (PM) -Cohort 2: Gestational trophoblastic tumors (GTT) -Cohort 3: B3 thymomas and thymic carcinomas (TET) -Cohort 4: Anaplastic thyroid carcinomas (ATC) -Cohort 5: GEP-NET & carcinoid tumors (GEP-NET/TCT/UP-NET) Patients will have advanced/metastatic cancers found to be progressive/resistant after at least one previous line of standard systemic treatment.
Start: 2025-09-16Target: 186Updated: 2026-01-07
PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.
Not yet recruitingCTIS2024-519753-11-00
Fondation Franc.Cancerologie DigestiveResectable borderline pancreatic adenocarcinoma
Target: 110Updated: 2025-10-17

Phase 3

Multicenter randomized Phase III trial evaluating contact X-ray brachytherapy for rectal preservation in intermediate substage rectal adenocarcinoma (TRESOR)
RecruitingCTIS2023-506885-30-00
Institut Gustave RoussyAdult patients with intermediate low or mid rectal adenocarcinoma to be treated with total neoadjuvant therapy (TNT) potentially eligible for rectal preservation.
Start: 2024-03-26Target: 212Updated: 2025-03-11